Tips to Use Phoenix WinNonlin More Efficiently Blog Tips to Use Phoenix WinNonlin More Efficiently Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…CertaraNovember 7, 2022
The Role of PBPK Modeling & Simulation in Infants & Neonates Blog The Role of PBPK Modeling & Simulation in Infants & Neonates Many factors make it challenging to obtain adequate pediatric samples for use in drug development…CertaraNovember 4, 2022
Why you should select your drug formulation before starting clinical studies Blog Why you should select your drug formulation before starting clinical studies Drug developers often rush through the discovery process to get into human testing. Most are…CertaraOctober 28, 2022
Accelerating Market Access with Data-Driven Payer Engagement Press Coverage Accelerating Market Access with Data-Driven Payer Engagement Using data visualizations to improve access to payers. With the switch to more digital environments,…CertaraOctober 25, 2022
Applications of PBPK modelling for regulatory submissions: case studies involving DDIs, transporters and special populations On-Demand Webinar Applications of PBPK modelling for regulatory submissions: case studies involving DDIs, transporters and special populations Over the past two decades, there have been transformative changes in our approach to using…CertaraOctober 20, 2022
Simultaneous FDA & EMA Submissions for Drug Approvals Press Coverage Simultaneous FDA & EMA Submissions for Drug Approvals Is there a better way? The question always breeds critical thinking and often leads to…CertaraOctober 19, 2022
RAPS sponsored webcast: The EU Clinical Trials Regulation – Challenges Drug Developers Faced in the First 6 months On-Demand Webinar RAPS sponsored webcast: The EU Clinical Trials Regulation – Challenges Drug Developers Faced in the First 6 months Join us on November 10th for this webcast being held in partnership with RAPS. The…CertaraOctober 17, 2022
PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside Blog PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside Next generation therapeutics Oligonucleotide drugs are unique among therapeutic modalities in that they don’t engage…CertaraOctober 14, 2022
PK Submit™ Overview Fact Sheet PK Submit™ Overview Learn how PK Submit accelerates NCA workflows and ensures regulatory compliance.CertaraOctober 12, 2022
Certara Announces New Release of PK Submit Announcement Certara Announces New Release of PK Submit PRINCETON, N.J.— October 12, 2022 – Certara, Inc., a global leader in drug development software,…CertaraOctober 12, 2022